Alzheimer 's Disease, Cancer, And Stroke

Alzheimer disease (AD) is the most common cause of dementia in the elderly, accounting for 65–70% of all cases (Jellinger, Janetzky, Attems, & Kienzl, 2008). The other dementias are of the Parkinson 's group, the fronto-temporal group and the vascular group. The total worldwide yearly costs for the treatment and care of patients suffering from dementia are estimated to be around 250 billion US dollars. The lifetime risk for AD between the ages of 65 and 100 is 33% for men and 45% for women with an annual increase of 1–2% in the seventh decade to almost 60% in the 10th decade with doubling every 5 years (Jellinger et al., 2008). AD is incurable, and thus represents a major public health problem. AD represents a challenge to humanity due to its relatively recent discovery, progressive nature of the illness, and complex diagnosis.

Alzheimer 's disease (AD) is a progressive degenerative disease of the brain from which there is no recovery. There are three brain abnormalities that are the hallmarks of the Alzheimer’s disease is initially caused by plaques buildup in the brain’s neurons as illustrated in figure 1. The support structure that allows the flow of the nutrients through the neurons gets damaged and ultimately there is loss of connection among the neurons and they die off (National Institute of Health, 2015). This causes the brain tissue to shrinks, which is called atrophies. All this ultimately lead the victim of this disease to face difficulties in governing emotions, recognize errors and patterns, coordinate movement, and remember. Ultimately, a person with AD loses all memory and mental functioning.

Alzheimer’s Disease has been one of the top leading causes of death in our country. It is understood that this disease is identified as an excess of the protein amyloid-ß within an increase of plaque (Seneff, Wainwright, and Mascitelli, 2010). Additionally, as the brain ages, it gets used to the inflammation and oxidative stress, so it is important to take the right amount of antioxidant micronutrients like vitamin C and vitamin E as well as anti-inflammatory macronutrients such as omega-3 polyunsaturated fatty acids to protect the brain from ageing (Whalley et. al, 2004). This is a devastating disease that affects most people over the age of fifty. Recently, there have been many studies done to figure out what causes this disease, if there is anything that can cure it, and how to prevent the disease. Seneff, Wainwright, and Mascitelli, believe Alzheimer’s develops with consuming too many carbohydrates, especially fructose and having a deficiency in cholesterol and dietary fats as well (2010). Whalley, Starr, and Deary have seen that poor diet, poverty, and failing health are links to developing Alzheimer’s Disease (2004). Furthermore, seeing increase in plasma homocysteine concentration increases risk of Dementia, which can result from an inadequate intake of vitamin B12/folate (Walley et. al, 2004). Additionally, Gray supports Walley’s findings and even believes having an adequate intake of vitamin B12/folate will have a positive effect on the overall health

The FDA recently has allowed two treatments to be used for Alzheimer patients. One of the treatments is a Partial Glutamate Antagonist, which is an important transmitter to the brain. It is said that Glutamate helps patients more than sugar pills do, however; it is said that too much

Alzheimer’s disease is a prominent brain disease that effects a massive amount of individuals in the United States. Alzheimer’s disease (AD) is the sixth leading cause of death in the United States, accounting for 60-80% of dementia cases, with no chance of being cured, prevented or decelerating over time (Alzheimer’s Association, 2014). AD is the most well-known form of dementia, causing complications in brain function in the areas of memory, thinking, and behavior (Alzheimer’s Association, 2014). In an effort to gain a deeper understanding of Alzheimer’s disease, researchers create new knowledge about the disease, which is then distributed to the public. The goal in this information disbursement is to find new and inventive ways to treat AD, prevent AD from progressing at such a rapid pace, and aid in the quality of life in those diagnosed with AD as well as caregivers and medical professionals providing treatment to individuals’ with AD.

Alzheimer’s disease is a complex illness that affects the brain tissue directly and undergoes gradual memory and behavioral changes which makes it difficult to diagnose. It is known to be the most common form of dementia and is irreversible. Over four million older Americans have Alzheimer’s, and that number is expected to triple in the next twenty years as more people live into their eighties and nineties. (Johnson, 1989). There is still no cure for Alzheimer’s but throughout the past few years a lot of progress has been made.

Alzheimer’s disease (AD) is a progressive and fatal form of dementia, frequently seen in the elderly altering their cognition, thought process and behavior. AD is reported in about half of patients that have a dementia diagnosis; one study states that about 10.3% of the population over 65 years is affected by dementia with an increase to almost 50% over the age of 8 (Beattie, 2002). Alzheimer’s disease is not a normal part of the aging process in humans, but rather found in a group of diseases that affect the brain leading to a decline in mental and physical control. AD when diagnosed has a very slow and gradual course, initially affecting the individual’s short term memory (Beattie, 2002). Alzheimer’s disease is the 6th leading cause of death, affecting more than five million people in the United States and is also one of the most common forms of dementia. Dementia can be defined as a disorder of progressive cognitive impairment severe enough to affect daily functions of an individual’s life (Fillit, et al., 2002).

Alzheimer 's disease (AD) is an irreversible and incurable form of dementia characterized by rapid cell death, neurofibrillary tangles, and neuritic plaques (Cavanaugh, Blanchard-Fields, & Norris, 2008). Structures of the brain affected by rapid cell death includes the hippocampus, the cerebral cortex, and the forebrain (Cavanaugh et al., 2008). A definitive diagnosis of AD is made only at autopsy (Cavanaugh et al., 2008). As AD progresses, memory and ultimately self-identity are destroyed, however, interventions can improve the quality of life of older adults (Cavanaugh et al., 2008). Interventions in AD should focus on helping patients make the most effective use of their functioning (Cavanaugh et al., 2008). A non-pharmacological intervention by Bredesen (2014) appears to be restoring some cognitive function in some patients with AD (Dador, 2014). Bredesen (2014) asserts that some of the effects of cognitive decline can be reversed through his therapeutic program. Jimbo, Kimura, Taniguchi, Inoue, and Urakami (2009) also assert the potential of non-pharmacological interventions. They found that aromatherapy has the potential to improve cognitive function. Other non-pharmacological interventions such as exercise or physical activity (PA) have been studied for their effects in cognitive decline (Farina, Rusted, & Tabet, 2014; Tortosa-Martinez & Clow, 2012). This paper explores the effects of non-pharmacological interventions in cognitive decline associated with AD.

Burcham and Rosentheal (2016) talk about a medication called Aricept. Aricept is a cholinesterase inhibitor that was approved by the FDA to treat early stages of Alzheimer's disease. Cholinesterase inhibitors prevent the breakdown of acetylcholine, a chemical in the brain and the body that helps to communicate with other cells in the body. For AD patients, Aricept would increase the amount of acetylcholine and improve the function of neuron that have not been destroyed. Furthermore, Aricept does not cure the disease, it helps delaying the disease and preventing symptoms form becoming worse.

Alzheimer's Disease is a condition that affects 50% of the population over the age of eighty five, which equals four million Americans each year. It is becoming an important and high-profile issue in today's society for everyone. There are rapid advancements being made in the fight against this disease now more than ever, and the purpose of this essay is to educate the public on the background as well as the new discoveries. There are many new drugs that are being tested and studied every day which slow down, and may even halt the progress of the disease.

Although Alzheimer’s disease (henceforth: AD) has been around since the 19th century or possibly even earlier and was at a point in time classified as senile dementia, it wasn’t until 1906 following Dr. Alois Alzheimer’s encounter with Auguste Deter at a Frankfurt asylum that the name of the disease was finally coined. Since then, major developments relating to the disease has taken place. In our report, we addressed some of the areas of the history, contemporary and prospects of the disease.

With 46.8 million people currently living with AD and the number of people to be diagnosed in the future set to rise, a study conducted by (Cummings, Morstorf & Zhong 2014) analysed the clinical trials associated with Alzheimer’s drug development throughout 2002 to 2012 in USA listed on clinicaltrials.gov. The united states undertakes the largest number of clinical trials compared to anywhere else in the world; in total 413 trials had and are being undertaken (Phase I-124, Pahse2-206, Phase 3- 83), but it was found that this number is relatively low in terms of addressing the magnitude of the problem with roughly 131.5 million people worldwide set to have AD by 2050 (Cummings, Morstorf & Zhong 2014; Prince et al. 2015).

Alzheimer's disease is officially listed as the sixth-leading cause of death in the United States. It is the fifth-leading cause of death for people age 65 and older (Alzheimer’s, 2016). I care for patients daily with Alzheimer’s, and it something dear to my heart. I’ve watched residents go through the transformation and stages as the disease progresses. It is truly heart breaking to see a resident that no longer can recognize a loved one’s face or name. Drug therapy does not cure Alzheimer’s disease and the definite cause is still unknown, however it works to help with cognitive and behavioral symptoms. The drugs help to assist with making the quality of life better for individuals with the disease. There are other non-drug therapies that

Medicines available for Alzheimer’s Disease (AD) do not reverse or stop its progression but they

Alzheimer’s, a common form of dementia, causes memory loss and other cognitive abilities that interfere with daily life. Alzheimer’s is a progressive disease that worsens over time. In its early stages, patients display symptoms of memory loss and eventually leads to stages where a person can no longer identify the environment they are in. although there is no cure for Alzheimer’s, there are treatments the can temporarily slow the progress of dementia. Because Alzheimer’s is considered one of the leading causes of death in the United States, it is important to find alternative treatments that can stop its development.